Clinical trial
8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS
NCT00230581 · Dynogen Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00230581 |
|---|---|
| Title | 8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS |
| Official title | A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Doses and Dose Levels of DDP225 in Female Patients With Irritable Bowel Syndrome With Diarrhea |
| Lead sponsor | Dynogen Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Irritable Bowel Syndrome |
| Intervention type | Drug |
| Interventions | DDP225 |
| Enrollment | 88 |
| Start date | Sep 1, 2005 |
| Completion | Aug 1, 2007 |
| First posted | Oct 3, 2005 |
| Last update posted | Oct 15, 2007 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: